Cost-effectiveness of oral versus intravenous antibiotics (OVIVA) in patients with bone and joint infection: evidence from a non-inferiority trial
Authors:
- Nicola McMeekinNMNicola McMeekin
- Claudia GeueCGClaudia Geue
- Andrew BriggsABAndrew Briggs
- Ines RombachIRInes Rombach
- Ho Kwong LiHLHo Kwong Li
- Philip BejonPBPhilip Bejon
- Martin McNallyMMMartin McNally
- Bridget L. AtkinsBABridget L. Atkins
- Jamie FergusonJFJamie Ferguson
- Matthew ScarboroughMSMatthew Scarborough
- Oviva CollaboratorsOCOviva Collaborators
Open Access
- 17 July 2019
- journal article
- Published by F1000 Research Ltd in Wellcome Open Research
- Vol. 4, 108
Abstract
Background: Bone and joint infections are becoming increasingly common and are usually treated with surgery and a course of intravenous antibiotics. However, there is no evidence to support the superiority of intravenous therapy and there is a growing body of literature showing that oral therapy is effective in treating these infections.Given this lack of evidence the clinical trial ‘Oral Versus Intravenous Antibiotics’ (OVIVA) was designed to assess the clinical and cost-effectiveness of intravenous versus oral antibiotics for the treatment of bone and joint infections, using a non-inferiority design. Clinical results from the trial indicate that oral antibiotics are non-inferior to intravenous antibiotics. The aim of this paper is to evaluate the cost-effectiveness of intravenous compared to oral antibiotics for treating bone and joint infections, using data from OVIVA. Methods: A cost-utility analysis was carried out, the main economic outcome measure was the quality adjusted life-year, measured using the EQ-5D-3L questionnaire, combined with costs to estimate cost-effectiveness over 12-months follow-up. Results: Results show that costs were significantly lower in the oral arm compared to the intravenous arm, a difference of £2,740 (95% confidence interval £1,488 to £3,992). Results of four sensitivity analyses were consistent with the base-case results. QALYs were marginally higher in the oral arm, however this difference was not statistically significant; -0.007 (95% confidence interval -0.045 to 0.031). Conclusions: Treating patients with bone and joint infections for the first six weeks of therapy with oral antibiotics is both less costly and does not result in detectable differences in quality of life compared to treatment with intravenous antibiotics. Adopting a practice of treating bone and joint infections with oral antibiotics early in the course of therapy could potentially save the UK National Health Service over £17 million annually.Keywords
Funding Information
- National Institute for Health Research (11/36/29)
- Wellcome Trust (205814)
This publication has 21 references indexed in Scilit:
- Economical Analysis on Prophylaxis, Diagnosis, and Treatment of Periprosthetic InfectionsThe Open Orthopaedics Journal, 2013
- Economic Evaluation of Chlorhexidine Cloths on Healthcare Costs due to Surgical Site Infections Following Total Knee ArthroplastyThe Journal of Arthroplasty, 2013
- Treatment of Periprosthetic Infections: An Economic AnalysisThe Scientific World Journal, 2013
- A financial analysis of revision hip arthroplastyThe Journal of Bone and Joint Surgery. British volume, 2012
- Systemic Antibiotic Therapy for Chronic Osteomyelitis in AdultsClinical Infectious Diseases, 2011
- Analyse du coût des reprises des prothèses totales de hanche infectéesRevue de Chirurgie Orthopédique et Traumatologique, 2010
- Estimating mean QALYs in trial‐based cost‐effectiveness analysis: the importance of controlling for baseline utilityHealth Economics, 2004
- Clinical Effectiveness and Cost-Effectiveness of 2 Management Strategies for Infected Total Hip Arthroplasty in the ElderlyClinical Infectious Diseases, 2001
- EuroQol - a new facility for the measurement of health-related quality of lifeHealth Policy, 1990
- The Analysis of Social Science Data with Missing ValuesSociological Methods & Research, 1989